Fuente: FierceBiotech After its bet on a rare eye disease gene therapy ended in a phase 3 fail, Johnson & Johnson is returning the asset to sender as MeiraGTx buys back back full rights to botaretigene sparoparvovec (bota-vec) for $25 million upfront.